Changes of health-associated quality of life (QоL) are an important criterion for evaluating the severity and treatment efficiency in patients with stable coronary artery disease. General and disease-specific questionnaires are used to assess QoL in contemporary clinical studies. The frequency of angina attacks is a key factor of QoL worsening in patients with stable coronary artery disease, independent from concomitant diseases and syndromes. Effort angina may lead to the decrease of physical activity level and ability to perform everyday activities, which in turn causes lifestyle changes and deterioration of QoL subjective perception. The use of the majority of contemporary antianginal drugs may be associated with «hemodynamic» side effects. Taking this into account, medications with metabolic mechanisms of antiischemic action, such as ranolazine, have a clear perspective. Ranolazine usage provides additional opportunities to improve QoL in patients with stable coronary artery disease, which may have a special value for treatment of the elderly patients.